Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group
Cancers · 10.06.2024 · 16 (12) · 2185
DOI: 10.3390/cancers16122185 ↗Kurz gefasst
Leitlinie in der Zeitschrift Cancers, online erschienen am 10.06.2024. Verfasst von Jérôme Paillassa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Service des Maladies du Sang, CHU d'Angers, 49000 Angers, France. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hairy-cell leukemia (HCL) is a rare B-cell chronic lymphoproliferative disorder (B-CLPD), whose favorable prognosis has changed with the use of purine nucleoside analogs (PNAs), such as cladribine (CDA) or pentostatin (P). However, some patients eventually relapse and over time HCL becomes resistant to chemotherapy. Many discoveries have been made in the pathophysiology of HCL during the last decade, especially in genomics, with the identification of the BRAFV600E mutation and cellular biology, including the importance of signaling pathways as well as tumor microenvironment. All of these new developments led to targeted treatments, especially BRAF inhibitors (BRAFis), MEK inhibitors (MEKis), Bruton’s tyrosine kinase (BTK) inhibitors (BTKis) and recombinant anti-CD22 immunoconjugates.
Results
The following major changes or additions were introduced in these updated guidelines: the clinical relevance of the changes in the classification of splenic B-cell lymphomas and leukemias; the increasingly important diagnostic role of BRAFV600E mutation; and the prognostic role of the immunoglobulin (IG) variable (V) heavy chain (H) (IGHV) mutational status and repertory. We also wish to insist on the specific involvement of bones, skin, brain and/or cerebrospinal fluid (CSF) of the disease at diagnosis or during the follow-up, the novel targeted drugs (BRAFi and MEKi) used for HCL treatment, and the increasing role of minimal residual disease (MRD) assessment.
Conclusion
Here we present recommendations for the diagnosis of HCL, treatment in first line and in relapsed/refractory patients as well as for HCL-like disorders including HCL variant (HCL-V)/splenic B-cell lymphomas/leukemias with prominent nucleoli (SBLPN) and splenic diffuse red pulp lymphoma (SDRPL).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service des Maladies du Sang, CHU d'Angers, 49000 Angers, France.
- Hématologie Biologique, Structure Fédérative D'oncogénétique Cyto-Moléculaire du CHU de Caen (SF-MOCAE), CHU de Caen, 14000 Caen, France.
- Unité MICAH, INSERM1245, Université Caen-Normandie, 14000 Caen, France.
- Service d'Hématologie, CHU Béni Messous, Alger 16308, Algeria.
- Service d'Hématologie, CHU de Casablanca, Casablanca 20000, Morocco.
- Service d'Hématologie, CHU Aziza Othmena, Tunis 1002, Tunisia.
ORCID-Profile: Elsa Maitre, Thomas Matthes, Cécile Tomowiak
Zitieren
APA
Paillassa, J., Maitre, E., Belarbi Boudjerra, N., Madani, A., Benlakhal, R., Matthes, T., Van Den Neste, E., Cailly, L., Inchiappa, L., Bekadja, M. A., Tomowiak, C., & Troussard, X. (2024). Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group. Cancers, 16(12), 2185. https://doi.org/10.3390/cancers16122185
Vancouver
Paillassa J, Maitre E, Belarbi Boudjerra N, Madani A, Benlakhal R, Matthes T, et al. Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group. Cancers. 2024;16(12):2185. doi:10.3390/cancers16122185
BibTeX
@article{Paillassa2024,
author = {Paillassa, Jérôme and Maitre, Elsa and Belarbi Boudjerra, Nadia and Madani, Abdallah and Benlakhal, Raihane and Matthes, Thomas and Van Den Neste, Eric and Cailly, Laura and Inchiappa, Luca and Bekadja, Mohammed Amine and Tomowiak, Cécile and Troussard, Xavier},
title = {Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group},
journal = {Cancers},
year = {2024},
volume = {16},
number = {12},
pages = {2185},
doi = {10.3390/cancers16122185}
}
EUVIMED